Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04808453 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of CPI-300 in Patients With Advanced Tumors
A Phase 1 study of Advanced Tumors, sponsored by Coordination Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT04808453: Completed Phase 1 study of Advanced Tumors, sponsored by Coordination Pharmaceuticals.
NCT04808453 is a Phase 1 study of Advanced Tumors that has completed, run by Coordination Pharmaceuticals. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04808453, a Phase 1 study of Advanced Tumors, has completed, sponsored by Coordination Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, open-label, single arm, non-randomized study of CPI-300 in patients with advanced tumors. CPI-300 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD).
Primary Outcome
To determine the maximum tolerated dose (MTD), which is defined as the highest dose level at which number of patients reporting a dose limiting toxicity (DLT) is less than or equal to 33%
Conditions Studied
Interventions
- DRUG CPI-300
Study Locations (4)
Arizona
- Honor Health Research Institute - Scottsdale
Florida
- Florida Cancer Specialists - Lake Mary
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 1 |
What the finished NCT04808453 record still lists
NCT04808453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Advanced Tumors appearing as the primary indexed condition, and to 1 intervention - of which CPI-300 is the first listed.
NCT04808453 reports a single indexed study location in Arizona, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04808453 about?
NCT04808453 is a clinical study titled "Phase I Study of CPI-300 in Patients With Advanced Tumors". This is a prospective, open-label, single arm, non-randomized study of CPI-300 in patients with advanced tumors. CPI-300 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD).
What is the current status of trial NCT04808453?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-06-15. Estimated completion is 2023-12-15.
What conditions does trial NCT04808453 study?
This clinical trial studies the following conditions: Advanced Tumors.
What interventions are being tested in trial NCT04808453?
The interventions under investigation include: CPI-300 (DRUG).
Who is sponsoring clinical trial NCT04808453?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04808453 being conducted?
This trial has 4 study locations across Arizona, Florida, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04808453's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI